EPISODE · Sep 19, 2025 · 14 MIN
The Field of Blood Cancers: How Have We Evolved
from Baptist Health Doc-to-Doc · host Baptist Health
In this episode of Doc to Doc, we explore groundbreaking advances in the treatment of blood cancers with two of the field’s leading experts:Dr. Guenther Koehne, Deputy Director and Chief of Blood and Marrow Transplant, Hematologic Oncology and Benign Hematology, and Dr. Firas El Chaer, Chief of Leukemia Services and Medical Director of Infusion — both from Baptist Health Miami Cancer Institute.From precision-targeted therapies and measurable residual disease (MRD) to cutting-edge immunotherapies like (CAR) T-cell therapy, BiTEs, and NK-cell approaches — we cover the evolving tools that are reshaping treatment protocols across leukemia, myeloma, MDS, and lymphoma.Topics Covered:✅ MRD-guided treatment decisions✅ Overcoming drug resistance with combination strategies✅ Targeted therapies for actionable mutations✅ The expanding role of CAR T, BiTEs, and NK cells✅ Clinical application and access at Baptist HealthIf you're an oncologist, hematologist, or transplant specialist navigating the complexity of hematologic malignancies — this conversation will help sharpen your clinical edge.🔔 Subscribe for more expert insights: @BaptistHealthSF📍 Learn more at MiamiCancerInstitute.com
Embed this episode
What this episode covers
In this episode of Doc to Doc, we explore groundbreaking advances in the treatment of blood cancers with two of the field’s leading experts: Dr. Guenther Koehne, Deputy Director and Chief of Blood and Marrow Transplant, Hematologic Oncology and Benign Hematology, and Dr. Firas El Chaer, Chief of Leukemia Services and Medical Director of Infusion — both from Baptist Health Miami Cancer Institute. From precision-targeted therapies and measurable residual disease (MRD) to cutting-edge immunothe...
Ready to play
The Field of Blood Cancers: How Have We Evolved
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.